

North Yorkshire & York Area Prescribing Committee

Summary of decisions made regarding new product requests considered at a meeting of the Committee on the 7th June 2023.

Classification of products:

- G** **Green drug** - Can be initiated and prescribed in all care settings **○**- Second line / alternative green drug.
- ASR** **Amber Specialist Recommendation drug** - Can be recommended by a specialist for initiation in primary care.
- ASI** **Amber Specialist Initiation drug** – Initiated by a specialist and transferred to primary care once the patient stabilised. In some cases there may be a further restriction for use outlined - these will be defined in each case.
- ASC** **Amber Shared Care drug** - These are specialist drugs which must be initiated by the specialist, but with the potential to transfer to primary care within written and agreed shared care protocols and according to the agreed process for transfer of care.
- R** **Red drug** - Drugs that should remain under the total responsibility of the specialist. Usually considered as “hospital only” drugs.
- BLACK** **Not Approved** - Drugs that have been considered by the APC or other approved body and are not approved for prescribing within North Yorkshire & York.
- GREY** **Not Reviewed** - Drugs that have not been reviewed by the APC yet. This usually means that no application has been received or that an application is in progress. These drugs are not normally considered appropriate for prescribing in North Yorkshire & York.



Product	Decision			Comments/notes
	Approved	Refused	Deferred	
1) Requests deferred from previous meeting				
TA877: Finerenone for treating chronic kidney disease in type 2 diabetes	✓ ASR			The formulary will reflect the TAG – ICB is the responsible commissioner. Monitoring requirements to be confirmed in letters to GP request GP prescribe for each individual patient.
2) New Requests				
Tranexamic acid nose drops			✓	Requested for Treatment of epistaxis in patients with Hereditary Haemorrhagic Telangiectasia (Osler-Weber-Rendu syndrome). Decision: decision deferred to confirm costings , place in therapy vs tamoxifen and oral tranexamic acid, and full references provided in application.
3) New formulations & extensions to use				
None				

DECISION SUMMARY

Product	Decision			Comments/notes
	Approved	Refused	Deferred	
5) Products considered by NICE				
TA879: Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic gastric or gastro-oesophageal junction cancer after anti-HER2 treatment (terminated appraisal)				The formulary will reflect the TAG – NHS England is the responsible commissioner. Received for information.
TA880: Tezepelumab for treating severe asthma	✓ R			The formulary will reflect the TAG – NHS England is the responsible commissioner.
6) Appeals against earlier decisions by the APC				
None				
7) Miscellaneous formulary decisions by the APC				
Alfentanil injection for the management of moderate to severe pain in palliative care patients	✓ ASI			Decision: Change RAG status in Harrogate from RED to AMBER specialist recommendation to align with Y&S formulary.
Clonidine patches for the treatment of dystonia in children	✓ R			Decision: Approve change in clonidine patches to RED to align with West Yorkshire ICS.
Dexcom ONE	✓ ASR			Decision: RAG status confirmed to match that of Freestyle Libre 2 agreed at April 2023 NY&Y APC.

The following documents/guidelines were presented to and approved at the June 2023 meeting of the APC:

- NY&Y Endocrinology formulary chapter review

The following guidelines were presented to and recommended for approval to the HNY IPMOC at the June 2023 meeting of the APC:

- Nil this month.

The following shared care guidelines were presented to and approved at the June 2023 meeting of the APC:

- Nil this month.

The following documents/guidelines were presented to the June 2023 meeting of the APC for comment:

- Nil this month.